Anti-Viral Drugs Market Projected to Gain Significant Value through 2032
In 2022, the global anti-viral drugs market is expected to be worth $59,596.8 million. The introduction of generic antiviral medicines, as well as increased awareness about the availability of various vaccines for viral infections, are affecting growth throughout the forecast period. Between 2022 and 2032, the overall demand for Anti-Viral Drugs is expected to grow at a CAGR of 3.9%, reaching around US$ 87,675.36 Million.
Anti-viral drugs are medications that are specifically used
to treat viral infections. Most anti-viral drugs, like antibiotics, are used to
treat specific viral infections, whereas a broad-spectrum anti-viral drug is
effective against a wide range of viruses. Antiviral drugs do not kill their
target pathogens; instead, they inhibit their growth.
The global anti-viral drugs market is expected to grow at a
moderate rate in the pharmaceutical market due to increased awareness, an
increase in diseased population, and the introduction of new drugs with
improved efficacy.
Several major patents, including Combivir, Sustiva,
Tenofovir, Tamiflu, Relenza, and Telbivudine, will expire during the forecast
period. The patent expirations of these blockbuster drugs are expected to spark
generic competition in the antivirals therapeutics market, making it more competitive.
Late-stage pipeline drugs are expected to enter the market,
positively affecting the market. Most antivirals are considered relatively
harmless to the host and are thus used to treat infections. They differ from
viricides, which are not medications but can destroy or deactivate virus
particles both outside and inside the body.
Anti-viral drugs are used to treat patients with herpes
viruses, HIV, influenza A and B viruses, and hepatitis B and C viruses.
Anti-viral Drugs Market: Key Players
Some of the key players in global anti-viral drugs market,
which are focusing on general molecular mechanisms of antiviral drugs rather
than therapies for individual viruses, include Roche, Gilead, GlaxoSmithKline,
Bristol-Myers-Squibb, Abbott, AstraZeneca, Cipla, Schering-Plough, Johnson
& Johnson, Merck & Co and others.
Browse More@ https://www.futuremarketinsights.com/reports/anti-viral-drugs-market
Key Segments Covered in the Anti-Viral Drugs
Industry Analysis
Anti-Viral Drugs Market by Product type:
- Hepatitis-C
antivirals
- HIV
antivirals
- Herpes
antivirals
- Hepatitis-B
antivirals
- Influenza
antivirals
- Others
(Pneumonia, Flu, etc.)
Anti-Viral Drugs Market by End-user:
- Hospitals
- Clinics
- Ambulatory
Surgical Centers
Comments
Post a Comment